Zito J M, Safer D J, dosReis S, Gardner J F, Boles M, Lynch F
School of Pharmacy, University of Maryland, Baltimore 21201, USA.
JAMA. 2000 Feb 23;283(8):1025-30. doi: 10.1001/jama.283.8.1025.
Recent reports on the use of psychotropic medications for preschool-aged children with behavioral and emotional disorders warrant further examination of trends in the type and extent of drug therapy and sociodemographic correlates.
To determine the prevalence of psychotropic medication use in preschool-aged youths and to show utilization trends across a 5-year span.
Ambulatory care prescription records from 2 state Medicaid programs and a salaried group-model health maintenance organization (HMO) were used to perform a population-based analysis of three 1-year cross-sectional data sets (for the years 1991, 1993, and 1995).
From 1991 to 1995, the number of enrollees aged 2 through 4 years in a Midwestern state Medicaid (MWM) program ranged from 146,369 to 158,060; in a mid-Atlantic state Medicaid (MAM) program, from 34,842 to 54,237; and in an HMO setting in the Northwest, from 19,107 to 19,322.
Total, age-specific, and gender-specific utilization prevalences per 1000 enrollees for 3 major psychotropic drug classes (stimulants, antidepressants, and neuroleptics) and 2 leading psychotherapeutic medications (methylphenidate and clonidine); rates of increased use of these drugs from 1991 to 1995, compared across the 3 sites.
The 1995 rank order of total prevalence in preschoolers (per 1000) in the MWM program was: stimulants (12.3), 90% of which represents methylphenidate (11.1); antidepressants (3.2); clonidine (2.3); and neuroleptics (0.9). A similar rank order was observed for the MAM program, while the HMO had nearly 3 times more clonidine than antidepressant use (1.9 vs 0.7). Sizable increases in prevalence were noted between 1991 and 1995 across the 3 sites for clonidine, stimulants, and antidepressants, while neuroleptic use increased only slightly. Methylphenidate prevalence in 2- through 4-year-olds increased at each site: MWM, 3-fold; MAM, 1.7-fold; and HMO, 3.1-fold. Decreases occurred in the relative proportions of previously dominant psychotherapeutic agents in the stimulant and antidepressant classes, while increases occurred for newer, less established agents.
In all 3 data sources, psychotropic medications prescribed for preschoolers increased dramatically between 1991 and 1995. The predominance of medications with off-label (unlabeled) indications calls for prospective community-based, multidimensional outcome studies.
近期有关使用精神药物治疗行为和情绪障碍学龄前儿童的报告,有必要进一步研究药物治疗的类型、范围趋势以及社会人口统计学相关性。
确定学龄前儿童使用精神药物的患病率,并展示5年期间的使用趋势。
利用来自2个州医疗补助计划和1个薪资制团体模式健康维护组织(HMO)的门诊护理处方记录,对3个1年横断面数据集(1991年、1993年和1995年)进行基于人群的分析。
1991年至1995年,中西部某州医疗补助(MWM)计划中2至4岁参保人数在146,369至158,060之间;中大西洋某州医疗补助(MAM)计划中参保人数在34,842至54,237之间;西北部一个HMO机构中参保人数在19,107至19,322之间。
每1000名参保者中3种主要精神药物类别(兴奋剂、抗抑郁药和抗精神病药)以及2种主要心理治疗药物(哌甲酯和可乐定)的总患病率、年龄特异性患病率和性别特异性患病率;比较1991年至×××年这3个地点这些药物的使用增加率。
1995年MWM计划中学龄前儿童(每1000人)的总患病率排名顺序为:兴奋剂(12.3),其中90%为哌甲酯(11.1);抗抑郁药(3.2);可乐定(2.3);抗精神病药(0.9)。MAM计划观察到类似的排名顺序,而HMO机构中可乐定的使用量几乎是抗抑郁药的3倍(1.9对0.7)。1991年至1995年期间,3个地点的可乐定、兴奋剂和抗抑郁药患病率均显著增加,而抗精神病药的使用仅略有增加。2至4岁儿童中哌甲酯的患病率在每个地点均有所增加:MWM计划增加了3倍;MAM计划增加了1.7倍;HMO机构增加了3.1倍。兴奋剂和抗抑郁药类别中先前占主导地位的心理治疗药物的相对比例有所下降,而较新的、使用尚不广泛的药物比例有所增加。
在所有3个数据来源中,1991年至1995年期间为学龄前儿童开具的精神药物显著增加。使用未标明适应证(未标记)药物的主导地位,需要开展基于社区的前瞻性多维度结局研究。